Syeda Masooma Jafri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Syeda Masooma Jafri has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Aiza Ahsan
Dow University of Health Sciences, Karachi, Pakistan
2 shared publications - Hasibullah Aminpoor
Faculty of Medicine, Kabul University of Medical Sciences, Kabul, Afghanistan
2 shared publications - Javeria Nawaz
Dow University of Health Sciences, Karachi, Pakistan
2 shared publications - Muhammad Sharjeel Abbas
Gomal Medical College, Khyber Medical University, Peshawar, Pakistan
2 shared publications - Raghabendra Kumar Mahato
Gandaki Medical College Teaching Hospital and Research Center, Pokhara, Nepal
2 shared publications - Rida Shakeel
Department of Surgery, Dow Medical College, Karachi, Pakistan
2 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Springer Nature in Cardio-Oncology
Carvedilol for prevention of cardiotoxicity in patients receiving anthracycline-based chemotherapy: a systematic review and meta-analysis
- 16 September 2026
- Published by Springer Nature in Cardio-Oncology
Open AccessCarvedilol for prevention of cardiotoxicity in patients receiving anthracycline-based chemotherapy: a systematic review and meta-analysis
- Open Access
- 23 June 2026
- Published by Springer Nature in Lasers in Medical Science
- Vol. 41 (1) , 124
Comparing fractional CO₂ laser and needling-based modalities in facial acne scar treatment: a comprehensive systematic review and meta-analysis
Facial acne scarring is a widely prevalent dermatological disease manifested as a permanent aftereffect of acne vulgaris. While fractional CO₂ laser and needling procedures are essential to treating atrophic acne scars, comparative and safety data remains limited. This systematic review and meta-analysis directly compares their efficacy and safety. According to PRISMA guidelines, PubMed, Cochrane, Google Scholar, and ClinicalTrials.gov were systematically searched. Only studies comparing fractional CO₂ laser with needling-based monotherapy treating facial atrophic acne scars in adults were included. A random-effects model was employed for meta-analysis using Review Manager (RevMan) to compare efficacy and safety outcomes. A total of 17 studies were included in the meta-analysis. For primary efficacy outcomes, the results were non-significant for mean scar score reduction (SMD: -1.08, 95% CI: [-2.48, 0.32], I² = 97%) or mean quantitative scar reduction (SMD: 0.12, 95% CI: [-0.80, 1.04], I² = 92%), with significant heterogeneity. However, categorical treatment success was significantly high for CO₂ laser (RR: 1.10, 95% CI: [1.01, 1.20], I² = 0%). For safety outcomes, fractional CO₂ laser showed significantly high risk of post-inflammatory hyperpigmentation (PIH) as compared to standard microneedling (RR: 3.04, 95% CI: [1.49, 6.21], I² = 3%), but showed significantly low pain scores as compared to RF microneedling (SMD: -0.74, 95% CI: [-1.27, -0.21], I² = 0%). No significant differences were found for erythema, crusting/scabbing, or edema. Both fractional CO₂ laser and microneedling procedures show comparable efficacy in treating atrophic acne scars, however, patient variables such as skin type, scar type, and possible complications should be taken into consideration. Moreover, further tailored therapies are crucial to treating acne scars with low risk for complications.
- 23 June 2026
- Published by Springer Nature in Lasers in Medical Science
- Vol. 41 (1) , 124
Open AccessComparing fractional CO₂ laser and needling-based modalities in facial acne scar treatment: a comprehensive systematic review and meta-analysis
Facial acne scarring is a widely prevalent dermatological disease manifested as a permanent aftereffect of acne vulgaris. While fractional CO₂ laser and needling procedures are essential to treating atrophic acne scars, comparative and safety data remains limited. This systematic review and meta-analysis directly compares their efficacy and safety. According to PRISMA guidelines, PubMed, Cochrane, Google Scholar, and ClinicalTrials.gov were systematically searched. Only studies comparing fractional CO₂ laser with needling-based monotherapy treating facial atrophic acne scars in adults were included. A random-effects model was employed for meta-analysis using Review Manager (RevMan) to compare efficacy and safety outcomes. A total of 17 studies were included in the meta-analysis. For primary efficacy outcomes, the results were non-significant for mean scar score reduction (SMD: -1.08, 95% CI: [-2.48, 0.32], I² = 97%) or mean quantitative scar reduction (SMD: 0.12, 95% CI: [-0.80, 1.04], I² = 92%), with significant heterogeneity. However, categorical treatment success was significantly high for CO₂ laser (RR: 1.10, 95% CI: [1.01, 1.20], I² = 0%). For safety outcomes, fractional CO₂ laser showed significantly high risk of post-inflammatory hyperpigmentation (PIH) as compared to standard microneedling (RR: 3.04, 95% CI: [1.49, 6.21], I² = 3%), but showed significantly low pain scores as compared to RF microneedling (SMD: -0.74, 95% CI: [-1.27, -0.21], I² = 0%). No significant differences were found for erythema, crusting/scabbing, or edema. Both fractional CO₂ laser and microneedling procedures show comparable efficacy in treating atrophic acne scars, however, patient variables such as skin type, scar type, and possible complications should be taken into consideration. Moreover, further tailored therapies are crucial to treating acne scars with low risk for complications.
- Open Access
- 15 June 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (6) , e70369
Moderate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
Background: High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its comparative effectiveness after PCI remains uncertain. Methods: We performed a systematic review and meta‐analysis according to PRISMA guidelines. PubMed, Cochrane Library, and ClinicalTrials.gov were searched through September 2025 for studies enrolling adults undergoing PCI and comparing moderate‐intensity statin plus ezetimibe therapy with high‐intensity statin therapy. The primary outcome was major adverse cardiovascular events (MACE), defined as all‐cause mortality, myocardial infarction (MI), stroke, and revascularization. Secondary outcomes included individual cardiovascular endpoints and safety outcomes such as new‐onset diabetes and rhabdomyolysis. Random‐effects models were used to calculate pooled risk ratios (RRs). Results: Nine studies involving 179 621 patients were included, the majority being observational studies. No significant difference was observed in MACE between treatment strategies (RR 0.96, 95% CI 0.81–1.12). Modest reductions were observed in cardiovascular mortality (RR 0.83, 95% CI 0.71–0.98) and MI (RR 0.74, 95% CI 0.58–0.95), although findings were non‐robust with wide prediction intervals. Revascularization rates were similar between groups. Subgroup analyses suggested lower heterogeneity in intermediate follow‐up and non‐ACS populations. Conclusions: Moderate‐intensity statin plus ezetimibe therapy may provide cardiovascular outcomes comparable to high‐intensity statins after PCI. However, persistent heterogeneity limits certainty, and large randomized trials are needed to confirm long‐term efficacy and safety.
- 15 June 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (6) , e70369
Open AccessModerate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
Background: High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its comparative effectiveness after PCI remains uncertain. Methods: We performed a systematic review and meta‐analysis according to PRISMA guidelines. PubMed, Cochrane Library, and ClinicalTrials.gov were searched through September 2025 for studies enrolling adults undergoing PCI and comparing moderate‐intensity statin plus ezetimibe therapy with high‐intensity statin therapy. The primary outcome was major adverse cardiovascular events (MACE), defined as all‐cause mortality, myocardial infarction (MI), stroke, and revascularization. Secondary outcomes included individual cardiovascular endpoints and safety outcomes such as new‐onset diabetes and rhabdomyolysis. Random‐effects models were used to calculate pooled risk ratios (RRs). Results: Nine studies involving 179 621 patients were included, the majority being observational studies. No significant difference was observed in MACE between treatment strategies (RR 0.96, 95% CI 0.81–1.12). Modest reductions were observed in cardiovascular mortality (RR 0.83, 95% CI 0.71–0.98) and MI (RR 0.74, 95% CI 0.58–0.95), although findings were non‐robust with wide prediction intervals. Revascularization rates were similar between groups. Subgroup analyses suggested lower heterogeneity in intermediate follow‐up and non‐ACS populations. Conclusions: Moderate‐intensity statin plus ezetimibe therapy may provide cardiovascular outcomes comparable to high‐intensity statins after PCI. However, persistent heterogeneity limits certainty, and large randomized trials are needed to confirm long‐term efficacy and safety.
- 15 June 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (7) , 172
Olanzapine for chemotherapy-induced nausea and vomiting in breast cancer: a systematic review and meta-analysis of prospective randomised controlled trials
Purpose Chemotherapy-induced nausea and vomiting (CINV) remains a significant problem for breast cancer patients receiving highly emetogenic chemotherapy despite routine antiemetic practice. In this systematic review and meta-analysis we aim to examine the efficacy and safety of olanzapine with regular antiemetic treatment for CINV prevention in breast cancer patients. Methods Following PRISMA 2020 standards, we searched PubMed, Cochrane Library, Google scholar, and ClinicalTrials.gov. We retrieved RCTs exclusively, comparing olanzapine with placebo or routine care in breast cancer patients undergoing anthracycline-based chemotherapy. The protocol was registered to PROSPERO (CRD420251087309). The primary outcomes assessed were complete response (defined as no emesis and no rescue medication use) and total control (defined as no nausea, no emesis, and no rescue medication use). Certainty of evidence was assessed using the GRADE approach. Results Four RCTs involving 857 patients were included. Compared with placebo or standard antiemetic therapy alone, olanzapine significantly improved complete response rates (4 studies, 857 patients; RR 1.58, 95% CI 1.35–1.85; I² = 0%) and total control (2 studies, 600 patients; RR 1.93, 95% CI 1.49–2.50; I² = 0%). Subgroup analysis showed no statistically significant difference between 5 mg and 10 mg doses. Olanzapine decreased acute nausea (3 studies, 377 patients; RR 1.32, 95% CI 1.03–1.69, I² = 63.4%) and delayed nausea (3 studies, 377 patients; RR 1.22, 95% CI 1.06–1.41, I² = 0%). The overall impact on nausea control was not statistically significant and showed considerable heterogeneity (3 studies, 377 patients; RR 1.42, 95% CI 0.48–4.15; I² = 88.0%). Subgroup analysis showed no statistically significant difference between 5 mg and 10 mg doses. Side effects, including sedation, fatigue, sleeplessness, extrapyramidal symptoms, and increased appetite were significantly attributable to olanzapine. GRADE assessment showed low certainty evidence for complete response, total control, and delayed nausea outcomes, while evidence for acute complete response, acute nausea control, and overall nausea control was rated very low certainty due to risk of bias, inconsistency, and imprecision. Conclusion Olanzapine significantly enhances CINV prevention in breast cancer patients, with positive outcomes for both 5 mg and 10 mg doses. Although increased sedation occurred, it was generally well-tolerated.
- 15 June 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (7) , 172
Olanzapine for chemotherapy-induced nausea and vomiting in breast cancer: a systematic review and meta-analysis of prospective randomised controlled trials
Purpose Chemotherapy-induced nausea and vomiting (CINV) remains a significant problem for breast cancer patients receiving highly emetogenic chemotherapy despite routine antiemetic practice. In this systematic review and meta-analysis we aim to examine the efficacy and safety of olanzapine with regular antiemetic treatment for CINV prevention in breast cancer patients. Methods Following PRISMA 2020 standards, we searched PubMed, Cochrane Library, Google scholar, and ClinicalTrials.gov. We retrieved RCTs exclusively, comparing olanzapine with placebo or routine care in breast cancer patients undergoing anthracycline-based chemotherapy. The protocol was registered to PROSPERO (CRD420251087309). The primary outcomes assessed were complete response (defined as no emesis and no rescue medication use) and total control (defined as no nausea, no emesis, and no rescue medication use). Certainty of evidence was assessed using the GRADE approach. Results Four RCTs involving 857 patients were included. Compared with placebo or standard antiemetic therapy alone, olanzapine significantly improved complete response rates (4 studies, 857 patients; RR 1.58, 95% CI 1.35–1.85; I² = 0%) and total control (2 studies, 600 patients; RR 1.93, 95% CI 1.49–2.50; I² = 0%). Subgroup analysis showed no statistically significant difference between 5 mg and 10 mg doses. Olanzapine decreased acute nausea (3 studies, 377 patients; RR 1.32, 95% CI 1.03–1.69, I² = 63.4%) and delayed nausea (3 studies, 377 patients; RR 1.22, 95% CI 1.06–1.41, I² = 0%). The overall impact on nausea control was not statistically significant and showed considerable heterogeneity (3 studies, 377 patients; RR 1.42, 95% CI 0.48–4.15; I² = 88.0%). Subgroup analysis showed no statistically significant difference between 5 mg and 10 mg doses. Side effects, including sedation, fatigue, sleeplessness, extrapyramidal symptoms, and increased appetite were significantly attributable to olanzapine. GRADE assessment showed low certainty evidence for complete response, total control, and delayed nausea outcomes, while evidence for acute complete response, acute nausea control, and overall nausea control was rated very low certainty due to risk of bias, inconsistency, and imprecision. Conclusion Olanzapine significantly enhances CINV prevention in breast cancer patients, with positive outcomes for both 5 mg and 10 mg doses. Although increased sedation occurred, it was generally well-tolerated.
- Open Access
- 7 May 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 21 (1)
Transcatheter edge-to-edge repair and left ventricular assist devices for secondary mitral regurgitation in advanced heart failure: a scoping review
Background: Secondary mitral regurgitation (SMR) worsens outcomes in advanced heart failure. Transcatheter edge-to-edge repair (TEER) and left ventricular assist device (LVAD) implantation represent advanced treatment options for patients with persistent symptoms despite guideline-directed medical therapy (GDMT). Methods: A scoping review using a PICO framework identified contemporary studies published up to 2025 involving adults with advanced heart failure (NYHA III–IV, INTERMACS 1–7) and ≥moderate SMR. Outcomes included mortality, heart failure hospitalizations, functional status, mitral regurgitation reduction, ventricular remodeling, complications, and quality of life. Results: Nine studies including over 2,000 patients were analyzed (mean age 60–72 years; LVEF 15–33%). TEER was associated with lower mortality and fewer heart failure hospitalizations compared with GDMT in selected patients. LVAD recipients generally had more advanced disease (predominantly INTERMACS 1–3) with higher early mortality but substantial functional improvement. TEER achieved MR ≤ 2 + in 84–99% of patients with low procedural complication rates (1–9%), whereas LVAD therapy demonstrated greater functional improvement but higher device-related complications. Conclusion: TEER is associated with improved outcomes in selected patients with advanced heart failure and SMR, while LVAD therapy remains essential for patients with end-stage disease requiring durable circulatory support.
- 7 May 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 21 (1)
Open AccessTranscatheter edge-to-edge repair and left ventricular assist devices for secondary mitral regurgitation in advanced heart failure: a scoping review
Background: Secondary mitral regurgitation (SMR) worsens outcomes in advanced heart failure. Transcatheter edge-to-edge repair (TEER) and left ventricular assist device (LVAD) implantation represent advanced treatment options for patients with persistent symptoms despite guideline-directed medical therapy (GDMT). Methods: A scoping review using a PICO framework identified contemporary studies published up to 2025 involving adults with advanced heart failure (NYHA III–IV, INTERMACS 1–7) and ≥moderate SMR. Outcomes included mortality, heart failure hospitalizations, functional status, mitral regurgitation reduction, ventricular remodeling, complications, and quality of life. Results: Nine studies including over 2,000 patients were analyzed (mean age 60–72 years; LVEF 15–33%). TEER was associated with lower mortality and fewer heart failure hospitalizations compared with GDMT in selected patients. LVAD recipients generally had more advanced disease (predominantly INTERMACS 1–3) with higher early mortality but substantial functional improvement. TEER achieved MR ≤ 2 + in 84–99% of patients with low procedural complication rates (1–9%), whereas LVAD therapy demonstrated greater functional improvement but higher device-related complications. Conclusion: TEER is associated with improved outcomes in selected patients with advanced heart failure and SMR, while LVAD therapy remains essential for patients with end-stage disease requiring durable circulatory support.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Efficacy and Safety of Lebrikizumab in the Treatment of Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Background: Atopic dermatitis is a chronic inflammatory skin condition characterized by eczematous lesions and pruritus, which can significantly impair quality of life. Biologics have been introduced for the treatment; however, due to safety concerns, investigations for these systemic drugs continue. Lebrikizumab, a monoclonal antibody inhibiting IL‐13, not only reduces the immunological response but also minimizes the destructive effects of these cytokines on skin barriers. This meta‐analysis was conducted to assess the efficacy and safety profile of lebrikizumab in patients with atopic dermatitis. Methods: A systematic review and meta‐analysis were conducted in accordance with the PRISMA guidelines. From conception until October 2025, literature was searched on PubMed, Embase, the Cochrane Library, and Scopus. Data were pooled from 4 studies comprising 1037 patients. Outcomes assessed include achievement of IGA (0.1) and ≥ 2‐point score from baseline to 16 weeks, EASI‐75 and EASI‐90 at 16 weeks, DLQI 4‐point improvement, DLQI, and reduction in sleep loss score and adverse events. Standardized mean differences (SMDs) or odds ratios (ORs) were calculated with 95% confidence intervals (CIs), and heterogeneity was examined using the I 2 statistic. Results: Lebrikizumab was significantly superior to placebo in achieving IGA (0.1) (OR = 2.88; 95% CI: 1.73 to 4.79; p < 0.001) and EASI‐75 (OR = 2.98; 95% CI: 1.76 to 5.05; p < 0.001) at Week 16. It was also associated with DLQI 4‐point improvement (OR = 3.99; 95% CI: 1.51 to 10.56; p = 0.005), pruritus NRS ≥ 4‐point improvement (OR = 2.80; 95% CI: 1.56 to 5.04; p = 0.006), and DLQI (MD = −2.13; 95% CI: −3.55 to −0.71) from baseline to 16 weeks. Higher rates of treatment‐emergent adverse events (TEAEs) (OD = 1.42; 95% CI: 1.07 to 1.89; p = 0.02) and moderate AEs (OD = 1.53; 95% CI: 1.04 to 2.25; p = 0.03) were associated with lebrikizumab. The risk of serious adverse effects and infections was comparable across the two groups. Conclusion: Lebrikizumab shows significant benefit in improving atopic dermatitis treatment by IGA (0.1), and ≥ 2‐point reduction, higher EASI‐75 response, and reduction in DLQI and pruritus score. However, lebrikizumab is associated with a higher risk of TEAS and moderate AEs.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessEfficacy and Safety of Lebrikizumab in the Treatment of Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Background: Atopic dermatitis is a chronic inflammatory skin condition characterized by eczematous lesions and pruritus, which can significantly impair quality of life. Biologics have been introduced for the treatment; however, due to safety concerns, investigations for these systemic drugs continue. Lebrikizumab, a monoclonal antibody inhibiting IL‐13, not only reduces the immunological response but also minimizes the destructive effects of these cytokines on skin barriers. This meta‐analysis was conducted to assess the efficacy and safety profile of lebrikizumab in patients with atopic dermatitis. Methods: A systematic review and meta‐analysis were conducted in accordance with the PRISMA guidelines. From conception until October 2025, literature was searched on PubMed, Embase, the Cochrane Library, and Scopus. Data were pooled from 4 studies comprising 1037 patients. Outcomes assessed include achievement of IGA (0.1) and ≥ 2‐point score from baseline to 16 weeks, EASI‐75 and EASI‐90 at 16 weeks, DLQI 4‐point improvement, DLQI, and reduction in sleep loss score and adverse events. Standardized mean differences (SMDs) or odds ratios (ORs) were calculated with 95% confidence intervals (CIs), and heterogeneity was examined using the I 2 statistic. Results: Lebrikizumab was significantly superior to placebo in achieving IGA (0.1) (OR = 2.88; 95% CI: 1.73 to 4.79; p < 0.001) and EASI‐75 (OR = 2.98; 95% CI: 1.76 to 5.05; p < 0.001) at Week 16. It was also associated with DLQI 4‐point improvement (OR = 3.99; 95% CI: 1.51 to 10.56; p = 0.005), pruritus NRS ≥ 4‐point improvement (OR = 2.80; 95% CI: 1.56 to 5.04; p = 0.006), and DLQI (MD = −2.13; 95% CI: −3.55 to −0.71) from baseline to 16 weeks. Higher rates of treatment‐emergent adverse events (TEAEs) (OD = 1.42; 95% CI: 1.07 to 1.89; p = 0.02) and moderate AEs (OD = 1.53; 95% CI: 1.04 to 2.25; p = 0.03) were associated with lebrikizumab. The risk of serious adverse effects and infections was comparable across the two groups. Conclusion: Lebrikizumab shows significant benefit in improving atopic dermatitis treatment by IGA (0.1), and ≥ 2‐point reduction, higher EASI‐75 response, and reduction in DLQI and pruritus score. However, lebrikizumab is associated with a higher risk of TEAS and moderate AEs.